Adaptive Biotechnologies (ADPT) Gross Profit (2018 - 2025)
Historic Gross Profit for Adaptive Biotechnologies (ADPT) over the last 8 years, with Q3 2025 value amounting to $70.5 million.
- Adaptive Biotechnologies' Gross Profit rose 17238.06% to $70.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $161.1 million, marking a year-over-year increase of 7473.21%. This contributed to the annual value of $94.2 million for FY2024, which is 1530.17% up from last year.
- Adaptive Biotechnologies' Gross Profit amounted to $70.5 million in Q3 2025, which was up 17238.06% from $35.3 million recorded in Q2 2025.
- Adaptive Biotechnologies' Gross Profit's 5-year high stood at $70.5 million during Q3 2025, with a 5-year trough of -$16.2 million in Q2 2023.
- Over the past 5 years, Adaptive Biotechnologies' median Gross Profit value was $19.6 million (recorded in 2024), while the average stood at $22.0 million.
- Its Gross Profit has fluctuated over the past 5 years, first tumbled by 18345.12% in 2023, then skyrocketed by 24145.44% in 2024.
- Over the past 5 years, Adaptive Biotechnologies' Gross Profit (Quarter) stood at $11.2 million in 2021, then surged by 180.24% to $31.5 million in 2022, then dropped by 24.15% to $23.9 million in 2023, then grew by 8.4% to $25.9 million in 2024, then skyrocketed by 172.38% to $70.5 million in 2025.
- Its Gross Profit was $70.5 million in Q3 2025, compared to $35.3 million in Q2 2025 and $29.4 million in Q1 2025.